200,000 Shares in Geron Co. (NASDAQ:GERN) Purchased by Diadema Partners LP

Diadema Partners LP bought a new position in Geron Co. (NASDAQ:GERN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 200,000 shares of the biopharmaceutical company's stock, valued at approximately $708,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Rovin Capital UT ADV boosted its stake in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 3,660 shares in the last quarter. Xponance Inc. increased its position in Geron by 12.9% during the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock worth $150,000 after purchasing an additional 4,829 shares during the last quarter. KBC Group NV raised its position in shares of Geron by 45.1% in the 4th quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 7,592 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of Geron in the 4th quarter valued at about $28,000. Finally, Lazari Capital Management Inc. grew its stake in Geron by 11.7% during the fourth quarter. Lazari Capital Management Inc. now owns 76,424 shares of the biopharmaceutical company's stock worth $271,000 after buying an additional 8,000 shares during the period. Institutional investors and hedge funds own 73.71% of the company's stock.

Geron Stock Performance

Shares of NASDAQ GERN remained flat at $1.42 during mid-day trading on Friday. 6,357,119 shares of the stock were exchanged, compared to its average volume of 11,506,865. The firm has a market capitalization of $904.42 million, a PE ratio of -4.44 and a beta of 0.66. Geron Co. has a 1-year low of $1.17 and a 1-year high of $5.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The stock has a fifty day simple moving average of $1.64 and a 200 day simple moving average of $2.92.

Geron (NASDAQ:GERN - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The company had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. On average, sell-side analysts anticipate that Geron Co. will post -0.25 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. HC Wainwright reissued a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 price target on shares of Geron in a report on Wednesday, March 12th. Barclays reissued an "overweight" rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th. Scotiabank decreased their target price on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a research report on Thursday, February 27th. Finally, Stifel Nicolaus cut their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.75.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.